Elexacaftor/tezacaftor/ivacaftor

Royalty Pharma Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 8, 2023

Drivers of total royalty receipts in the third quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the third quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired the Spinraza royalty in the first quarter of 2023.
  • In September 2023, Royalty Pharma acquired a royalty interest in Skytrofa from Ascendis Pharma A/S ( press release ) for an upfront payment of $150 million.
  • During the third quarter of 2023, Royalty Pharma repurchased approximately five million shares for $144 million.

Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference

Retrieved on: 
Thursday, November 2, 2023

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (CF) in ~90% of people with the disease, will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) taking place November 2-4, 2023 in Phoenix, Arizona.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (CF) in ~90% of people with the disease, will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) taking place November 2-4, 2023 in Phoenix, Arizona.
  • Presentations will highlight results from two open-label extension studies demonstrating the long-term clinical benefits and safety profile of TRIKAFTA® among CF pediatric populations.
  • Vertex will present interim data on TRIKAFTA® from its longest pediatric follow-up study to date.
  • The data also showed a continued favorable safety profile, with no new safety findings (Poster #133).

Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences

Retrieved on: 
Thursday, September 14, 2023

“The research teams led by Paul, Fred and Sabine discovered the first and only medicines that address the underlying cause of cystic fibrosis.

Key Points: 
  • “The research teams led by Paul, Fred and Sabine discovered the first and only medicines that address the underlying cause of cystic fibrosis.
  • Vertex is currently developing a next-in-class investigational CF triple combination therapy, now in Phase 3 trials, that has the potential for enhanced clinical benefit.
  • The Breakthrough Prize in Life Sciences was founded in 2013 by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Yuri and Julia Milner, and Anne Wojcicki.
  • Breakthrough Prizes are also awarded annually in the fields of Fundamental Physics and Mathematics.

Royalty Pharma Reports Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023

Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).

Key Points: 
  • Drivers of total royalty receipts in the second quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • During the second quarter of 2023, Royalty Pharma began repurchasing its Class A ordinary shares and repurchased approximately four million shares for $134 million.
  • The weighted-average diluted Class A ordinary shares outstanding for the second quarter of 2023 was 606 million as compared to 607 million for the first quarter of 2023.

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Retrieved on: 
Friday, June 9, 2023

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines were presented at this year’s European Cystic Fibrosis Society's (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines were presented at this year’s European Cystic Fibrosis Society's (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria.
  • Together, the data presented show the long-term benefits of treatment with CFTR modulators as well as the importance of treating the underlying cause of CF as early in life as possible.
  • Key data presented at this year’s conference are highlighted below.
  • “The data on TRIKAFTA in particular demonstrate that this medicine improves lung function sustainably and in a real-world setting.

Royalty Pharma Reports First Quarter 2023 Results

Retrieved on: 
Tuesday, May 9, 2023

As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.

Key Points: 
  • As such, Royalty Pharma did not receive royalty receipts on Prevymis net sales in the first quarter of 2023 related to the fourth quarter of 2022.
  • Drivers of royalty receipts in the first quarter of 2023 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
  • Royalty Pharma acquired a royalty interest in Trelegy in July 2022 and began receiving royalty receipts in the third quarter of 2022.
  • Royalty Pharma will also receive 25% of Ionis’ mid-teens to low-20% royalty on net sales of pelacarsen, resulting in a mid-single digit royalty to Royalty Pharma.

Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations

Retrieved on: 
Wednesday, April 26, 2023

“Since its initial approval, TRIKAFTA has had a significant impact on the CF community, transforming the lives of thousands of people living with cystic fibrosis,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex.

Key Points: 
  • “Since its initial approval, TRIKAFTA has had a significant impact on the CF community, transforming the lives of thousands of people living with cystic fibrosis,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex.
  • The data from this study were recently published in the American Journal of Respiratory and Critical Care Medicine .
  • Additionally, Vertex has submitted applications for the use of TRIKAFTA®/KAFTRIO® in children ages 2 through 5 years of age to other global regulatory authorities, including the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA).
  • For more information on TRIKAFTA®, patient assistance programs or to find additional eligibility details, visit TRIKAFTA.com , VertexGPS.com or vertextreatments.com .

Royalty Pharma Declares Third Quarter 2022 Dividend

Retrieved on: 
Friday, July 15, 2022

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share.

Key Points: 
  • NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share.
  • The dividend will be paid on September 15, 2022, to shareholders of record at the close of business on August 19, 2022.
  • Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022

Retrieved on: 
Thursday, July 14, 2022

NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open.

Key Points: 
  • NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open.
  • The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
  • Please visit the Investors page of the companys website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference call information and to view the live webcast.
  • Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industrys leading therapies.

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Retrieved on: 
Wednesday, July 13, 2022

In 2021, Trelegy generated sales of $1.68 billion, an increase of 57% at constant exchange rates versus the prior year.

Key Points: 
  • In 2021, Trelegy generated sales of $1.68 billion, an increase of 57% at constant exchange rates versus the prior year.
  • We are excited to acquire this royalty from Theravance and Innoviva, said Pablo Legorreta, Royalty Pharmas founder and Chief Executive Officer.
  • Royalty Pharma is acquiring from Theravance and Innoviva all of the equity interests in Theravance Respiratory Company, LLC, which is entitled to an upward tiering royalty of 6.5% to 10% on annual worldwide Trelegy sales, payable by GSK.
  • In exchange, Royalty Pharma will receive a low- to mid-single digit royalty on worldwide sales of ampreloxetine.